Velocity Clinical Research Expands into Latin America with New MD

Velocity Clinical Research Targets Latin America with New Leadership

Velocity Clinical Research, recognized as a leader in integrated clinical site operations, is making significant strides in targeting Latin America for expansion. The company has recently appointed Renata Berardocco as the Managing Director for the LATAM region, a move that highlights Velocity's ambitious growth plans. With nearly two decades of experience in the industry, Berardocco's background positions her to effectively steer the company's operations in Latin America.

The Importance of Latin America in Clinical Research

Latin America is becoming increasingly vital in clinical research, representing approximately 10% of the world's clinical research sites. With a growing demand for clinical trials, the region is a focal point for Velocity’s strategic expansion. Velocity has already seen remarkable growth in Europe, establishing 17 clinical trial sites across multiple countries, which only fuels their momentum moving forward.

Renata Berardocco's Expertise and Vision

Renata Berardocco's career spans significant roles in leading clinical operations and delivering project results. Her previous tenure at Fortrea showcases her strengths in managing large teams and navigating complex clinical environments. She has also contributed to establishing clinical frameworks in Brazil, gaining firsthand experience in government sales and strategic site operations.

As the newly appointed LATAM Managing Director, Berardocco will play a pivotal role in guiding the identification and operation of new sites across the region. She aims to leverage her extensive network and demonstrate Velocity’s model of patient recruitment and site management in Brazil, Argentina, and Mexico, which account for a significant portion of the LATAM market.

The Velocity Advantage in Clinical Trials

Velocity's approach offers numerous benefits, such as enhanced patient enrollment efficiency, consistent data collection, and overall improved quality control in clinical trials. The company thrives on technology and innovative strategies that not only bolster trial efficacy but also increase patient safety and data integrity. With this foundation, Berardocco is set to optimize these workflows within the LATAM framework.

Fast-Paced Growth and Future Prospects

Velocity Clinical Research has undergone rapid expansion, solidifying its position as a major player in the clinical trial landscape. Currently, Velocity operates over 90 sites globally, employing more than 1,500 staff members, including 220 Principal Investigators. This model of scalability and flexibility has positioned the company to meet the rising demand for clinical research in diverse markets.

A Bright Future for Velocity

Looking ahead, the integration of the LATAM operations under Berardocco’s guidance comes at a crucial time. Enhanced collaboration with local healthcare providers and Principal Investigators is essential for reducing trial timelines and improving patient outcomes. Velocity's expansion into Latin America signals their commitment to innovation and global reach in clinical research.

Commitment to High-Quality Research

Velocity's operations have shown that investing in quality and technology fosters a conducive environment for clinical trials. By developing unique platforms and harnessing extensive site and patient data, the company continues to redefine clinical trial capabilities, thereby ensuring that they remain at the forefront of their industry.

Frequently Asked Questions

What is the role of Renata Berardocco at Velocity Clinical Research?

Renata Berardocco is appointed as the LATAM Managing Director, leading the expansion of Velocity's operations in Latin America.

Why is Latin America important for clinical research?

Latin America represents about 10% of the world's clinical research sites and offers significant patient populations, which is crucial for diverse clinical trials.

How does Velocity Clinical Research enhance trial efficiency?

Velocity improves trial efficiency through enhanced patient recruitment, consistent data collection, and innovative technology solutions.

What is Velocity's growth strategy moving forward?

Velocity aims to expand its presence in LATAM, focusing on Brazil, Argentina, and Mexico, while maintaining high-quality operational standards.

How many sites does Velocity operate worldwide?

Velocity currently operates over 90 clinical trial sites globally, employing more than 1,500 personnel.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.